Endocrinology Book

http://www.fpnotebook.com/

SibutramineAka: Meridia

Advertisement

  1. Dosing
    1. Continuous: Sibutramine 15 mg qd
    2. Intermittent (similar weight loss, less side effects)
      1. Weeks 1-12: Sibutramine 15 mg qd
      2. Weeks 19-30: Sibutamine 15 mg qd
      3. Weeks 37-48: Sibutramine 15 mg qd
      4. No medication taken in other weeks
      5. Wirth (2001) JAMA 286:1331
  2. Efficacy: One year study
    1. Placebo group weight loss: 3.8 kg in 48 weeks
    2. Continuous Sibutramine: 7.9 kg in 48 weeks
    3. Intermittent Sibutramine: 7.8 kg in 48 weeks
    4. Wirth (2001) JAMA 286:1331
  3. Mechanism
    1. Monoamine reuptake inhibitor Antidepressant
      1. Serotonin and Norepinephrine reuptake inhibitor
      2. Similar to Effexor
    2. Effects (dose dependent)
      1. Enhances satiety
      2. Increases energy expenditure (metabolic rate)
  4. Adverse effects (Very similar to Effexor)
    1. Reduced adverse effects with intermittent treatment
    2. Common
      1. Diastolic Hypertension (2-10 mmHg increase)
        1. Optimize Blood Pressure control before use
      2. Tachycardia
      3. Insomnia
    3. Less common
      1. Headache
      2. Irritability
      3. Dry Mouth
      4. Dry Skin or rash

sibutramine (C0074493)

ConceptsOrganic Chemical (T109) , Pharmacologic Substance (T121)
Englishsibutramine, SIBUTRAMINE PREPARATION, Sibutramine product
Spanishsibutramina
Parent ConceptsCyclobutanes (C0010556), Centrally acting appetite suppressant (C0355335), Appetite Depressants (C0003620), Duplicate concept (C1274013), Drug allergen (C1320237)
SourcesMSH, NDFRT, RXNORM, SCTSPA, SNOMEDCT, VANDF
Derived from the NIH UMLS (Unified Medical Language System)


Meridia (C0635898)

ConceptsOrganic Chemical (T109) , Pharmacologic Substance (T121)
EnglishMeridia
SourcesMSH, NCI, RXNORM
Derived from the NIH UMLS (Unified Medical Language System)



Navigation Tree